A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

NCT00627926 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1095

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

BIOLOGICAL: Pegylated Interferon Alfa 2a
DRUG: Telaprevir
DRUG: Ribavirin
OTHER: Placebo

Sponsor

Vertex Pharmaceuticals Incorporated

Collaborators

[object Object]